| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 25.40 | -2.72% | 17.63万 | 4.48亿 | | 301584 | 建发致新 | 28.92 | -1.30% | 13.29万 | 3.81亿 | | 666509 | 益丰药房 | 25.11 | -0.83% | 8.35万 | 2.09亿 | | 600829 | 人民同泰 | 8.19 | -0.36% | ﻟ 6.28万 | 5104.30万 | | 301015 | 自注医药 | 25.70 | -0.35% | 3.02万 | 7760.09万 | | 603883 | 老百姓 | 16.66 | 0.18% | 8.65万 | 1.44亿 | | 000028 | 国药一致 | 25.34 | 0.20% | 1.99万 | 5052.26万 | | 601607 | 上海医药 | 18.25 | 0.27% | 12.39万 | 2.26亿 | | 002788 | 醫症医药 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-063 湖南达嘉维康医药产业股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）为满足公司全资 子公司及控股子公司日常生产经营和业务发展资金需要，保证公司业务顺利开展， 公司于 2025 年 4 月 17 日、2025 年 5 月 12 日分别召开的第四届董事会第十四次会 议及 2024 年年度股东大会审议通过《关于 2025 年度担保额度预计的议案》，同意 公司 2025 年度为公司全资子公司及控股子公司提供担保，担保额度预计不超过 30 亿 元。具体内容详见公司于 2025 年 4 月 21 日在巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于 2025 年度担保额度预计的公告》（公告编号：2025-026）。 4、法定代表人：王毅清 5、成立日期：2004 年 6 月 1 日 6、经营范围：许可项目：药品生产（不含中药饮片的蒸、炒、炙、煅等炮制技术 的应用及中 ...

证券之星消息，10月20日医疗耗材供应链SPD板块较上一交易日上涨0.41%，建发致新领涨。当日上证指 数报收于3863.89，上涨0.63%。深证成指报收于12813.21，上涨0.98%。医疗耗材供应链SPD板块个股涨 跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301584 | 建发致新 | 29.30 | 4.46% | 18.64万 | 5.34 Z | | 301126 | 达嘉维康 | 11.75 | 3.07% | 5.35万 | 6221.88万 | | 605186 | 健摩信息 | 19.55 | 2.68% | 1.72万 | 3343.23万 | | 603122 | 合富中国 | 6.40 | 1.91% | 4.41万 | 2806.45万 | | 300288 | 朗玛信息 | 13.68 | 1.48% | 3.64万 | 4968.35万 | | 603716 | 塞力医疗 | 26.11 | 1.48% | 19.46万 | 5.03亿 | ...

Core Viewpoint - As of October 10, 2025, the number of shareholders for Dajia Weikang (301126) is reported to be 15,931 [1] Company Summary - Dajia Weikang has engaged with investors through an interactive platform, providing updates on shareholder numbers [1] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [1]

证券之星消息，10月10日医药商业板块较上一交易日上涨0.17%，国发股份领涨。当日上证指数报收于 3897.03，下跌0.94%。深证成指报收于13355.42，下跌2.7%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600538 | 国发股份 | 5.85 | 4.28% | 17.88万 | 1.03亿 | | 301126 | 达嘉维康 | 11.34 | 1.89% | 4.30万 | 4865.55万 | | 000411 | 英特集团 | 11.49 | 1.77% | 5.54万 | 6322.58万 | | 603368 | 柳药集团 | 19.20 | 1.75% | 12.10万 | 2.31亿 | | 002788 | 營荷医药 | 8.24 | 1.60% | 5.35万 | 4399.24万 | | 600829 | 人民同泰 | 8.04 | 1.26% | 4.07万 | 3257.88万 | | 600713 | 南京医药 | ...

Core Viewpoint - The company is closely monitoring market conditions and policy changes, ensuring that its operations remain normal and orderly without being affected by tariffs [1] Company Operations - The company confirmed that all aspects of its production and operations are currently running smoothly and are not impacted by tariff changes [1]

Group 1 - On September 25, Dajia Weikang's stock price fell by 1.40%, with a trading volume of 29.55 million yuan [1] - The financing data on the same day showed a financing buy-in of 1.99 million yuan and a financing repayment of 4.18 million yuan, resulting in a net financing buy of -2.18 million yuan [1] - As of September 25, the total balance of margin trading for Dajia Weikang was 81.06 million yuan, which accounts for 3.50% of its market capitalization [1] Group 2 - As of September 19, the number of shareholders for Dajia Weikang was 16,000, a decrease of 2.90% from the previous period [2] - The average circulating shares per person increased by 2.99% to 8,629 shares [2] - For the first half of 2025, Dajia Weikang reported operating revenue of 2.708 billion yuan, a year-on-year increase of 4.16%, while the net profit attributable to the parent company was 893,500 yuan, a significant decrease of 97.19% [2] Group 3 - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders included Nu'an Multi-Strategy Mixed A (320016), which held 939,800 shares as a new shareholder [3]

Group 1: Financial Performance - The company achieved a revenue of 270,833.74 million CNY in the first half of 2025, representing a 4.16% increase compared to the same period last year [1] - The net profit attributable to shareholders was 893,533.16 CNY, showing a decline compared to the previous year [1] Group 2: Strategic Focus - The company is transitioning from traditional business growth models to a focus on innovation, high-quality, and diversified operations [1] - Emphasis on developing products and technologies in the field of regenerative medicine to enhance research innovation and clinical transformation [2] Group 3: Cost Management and Profitability - The company aims to strengthen cost control to reduce expenses in production, operations, and management, thereby improving profit margins [2] - The goal is to stabilize company performance and enhance profitability [2] Group 4: Investment Value and Market Position - The company is committed to solidifying its core competitiveness and profitability through talent development and leveraging existing business [2] - The company is poised to capitalize on opportunities in the healthcare industry to enhance its market position and service quality [2] Group 5: Regulatory Environment - Recent government policies promoting consumption and easing market access for high-end medical services are seen as positive signals for the company [2] - The company will closely monitor market demand and actively apply for relevant licenses in response to the new policy environment [2]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-062 湖南达嘉维康医药产业股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）为满足公司全资 子公司及控股子公司日常生产经营和业务发展资金需要，保证公司业务顺利开展， 公司于 2025 年 4 月 17 日、2025 年 5 月 12 日分别召开的第四届董事会第十四次会 议及 2024 年年度股东大会审议通过《关于 2025 年度担保额度预计的议案》，同意 公司 2025 年度为公司全资子公司及控股子公司提供担保，担保额度预计不超过 30 亿 元。具体内容详见公司于 2025 年 4 月 21 日在巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于 2025 年度担保额度预计的公告》（公告编号：2025-026）。 二、对外担保进展情况 近日，公司与中国民生银行股份有限公司长沙分行（以下简称"民生银行"） 签订了《最高额保证合同》，同意为全资子公司湖南达嘉维康医药有 ...

Group 1 - On September 15, Dajia Weikang's stock price fell by 0.59%, with a trading volume of 27.33 million yuan [1] - The financing data on the same day showed a financing purchase amount of 2.91 million yuan and a financing repayment of 4.03 million yuan, resulting in a net financing outflow of 1.13 million yuan [1] - As of September 15, the total balance of margin trading for Dajia Weikang was 88.47 million yuan, accounting for 3.62% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of September 10, the number of shareholders for Dajia Weikang was 16,500, an increase of 0.40% from the previous period, while the average circulating shares per person decreased by 0.39% to 8,378 shares [2] - For the first half of 2025, Dajia Weikang achieved an operating income of 2.708 billion yuan, a year-on-year increase of 4.16%, but the net profit attributable to the parent company was only 893,500 yuan, a significant decrease of 97.19% year-on-year [2] Group 3 - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders included the newly entered Noan Multi-Strategy Mixed A fund, holding 939,800 shares [3]